Business Context and Reporting Period
Company: pSivida Corp. (Note: Input metadata listed "Eyepoint, Inc.", but the filing text identifies the registrant as pSivida Corp.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Overview: pSivida is a drug delivery company focused on ophthalmology and oncology. It holds FDA-approved products (Retisert, Vitrasert) licensed to Bausch & Lomb. Its primary development candidate is Iluvien (for diabetic macular edema), developed in collaboration with Alimera Sciences. It also holds rights to BioSilicon technology, with BrachySil as a key oncology candidate.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2008 | Three Months Ended Sep 30, 2007 |
|---|---|---|
| Total Revenues | $2,806,000 | $103,000 |
| Net Loss | $(471,000) | $(795,000) |
| Loss Per Share (Basic/Diluted) | $(0.03) | $(0.04) |
| Cash and Cash Equivalents (End of Period) | $10,982,000 | $16,454,000 |
| Net Cash Used in Operating Activities | $(4,486,000) | $(4,264,000) |
| Total Assets | $47,161,000 | $55,784,000 (Jun 30, 2008) |
| Total Liabilities | $19,837,000 | $25,706,000 (Jun 30, 2008) |
| Stockholders' Equity | $27,324,000 | $30,078,000 (Jun 30, 2008) |
Debt and Liquidity: The company reported no borrowings or line of credit facilities as of September 30, 2008. It holds a note receivable of $667,000 (net of allowance). Management believes current cash resources, combined with expected collaboration payments, will fund operations through at least June 30, 2010.
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased by 2,624% to $2.8 million, driven almost entirely ($2.76 million) by the amended collaboration agreement with Alimera Sciences. This agreement recognized $18.3 million in deferred revenue to be amortized through December 2009.
- Operating Expenses: Total operating expenses decreased slightly by 2% to $5.2 million. Research and Development (R&D) expenses dropped 36% to $2.2 million because Alimera assumed financial responsibility for Iluvien development. Conversely, General and Administrative (G&A) expenses rose 60% to $3.0 million, primarily due to a $633,000 provision for losses on a note receivable from GEM Global Yield Fund.
- Derivative Income: Income from the change in fair value of derivatives decreased by 68% to $1.3 million (from $4.2 million), attributed to fluctuations in the company's share price affecting the valuation of Australian dollar-denominated warrants.
- Net Loss Improvement: Net loss narrowed by 41% to $471,000, aided by the revenue increase and a $485,000 income tax benefit from foreign R&D credits.
Outlook, Risks, and Management Commentary
- Liquidity Outlook: Management expects to fund operations through June 30, 2010, contingent on continued funding from Pfizer ($500k/quarter) and Alimera, and the eventual resumption of Retisert royalties from Bausch & Lomb (currently retained by B&L until $2.4 million is recovered).
- Key Milestones: Iluvien is in fully recruited Phase III trials. A $25 million milestone payment is due from Alimera upon FDA approval. BrachySil has completed initial safety trials for pancreatic cancer and commenced dose-ranging trials.
- Internal Control Weakness: The company disclosed a material weakness in internal controls over financial reporting regarding the accounting for complex transactions (specifically currency translation for the CDS acquisition). While remediation efforts are underway, disclosure controls were deemed ineffective as of September 30, 2008.
- Risks: Significant risks include the inability to raise capital in a difficult credit market, failure of product candidates to achieve regulatory approval, and dependence on strategic partners (Alimera, Pfizer, Bausch & Lomb) for funding and commercialization.
Investor Verification Checklist
- Collaboration Stability: Verify the status of the Alimera and Pfizer agreements, as they are the primary sources of near-term revenue and funding.
- Cash Burn Rate: Monitor quarterly cash usage against the $11 million cash balance to confirm the runway extends to mid-2010 without dilutive financing.
- Note Receivable Recovery: Assess the likelihood of recovering the remaining $667,000 from the GEM Global Yield Fund note, which was recently written down significantly.
- Internal Control Remediation: Review future filings to confirm the material weakness in financial reporting controls has been fully remediated.
- Derivative Liability Volatility: Monitor the $600,000 derivative liability, as changes in the company's stock price will directly impact reported earnings.